Short Interest in Biomerica, Inc. (NASDAQ:BMRA) Increases By 123.2%

Biomerica, Inc. (NASDAQ:BMRA) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 92,289 shares, an increase of 123.2% from the December 15th total of 41,348 shares. Approximately 3.8% of the shares of the company are short sold. Based on an average daily trading volume, of 234,834 shares, the short-interest ratio is currently 0.4 days. Based on an average daily trading volume, of 234,834 shares, the short-interest ratio is currently 0.4 days. Approximately 3.8% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Biomerica in a research note on Tuesday, October 14th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Biomerica currently has an average rating of “Sell”.

Biomerica Price Performance

Shares of NASDAQ:BMRA opened at $2.68 on Friday. The stock has a market cap of $7.91 million, a price-to-earnings ratio of -2.79 and a beta of 0.11. Biomerica has a 12 month low of $2.11 and a 12 month high of $10.16. The stock’s 50 day moving average price is $2.48 and its 200 day moving average price is $2.87.

Biomerica (NASDAQ:BMRA) last issued its quarterly earnings results on Wednesday, January 14th. The company reported ($0.45) earnings per share (EPS) for the quarter. Biomerica had a negative net margin of 90.29% and a negative return on equity of 81.62%. The firm had revenue of $1.21 million for the quarter.

Biomerica Company Profile

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.